Revimmune temporarily eliminates peripheral immune cells, including the immune cells causing the autoimmunity, while selectively sparing hematopoeitic stem cells in the bone marrow. Investigators at Johns Hopkins discovered that stem cells uniquely have high levels of a particular protective enzyme that can be measured in advance of therapy, which makes them impervious to Revimmune, and allows the surviving stem cells to give rise to a new immune system over two to three weeks

---

Accentia files preliminary IND for MS drug
Pharmaceutical Business Review - USA
Investigators at Johns Hopkins discovered that stem cells uniquely have high levels of a particular protective enzyme that can be measured in advance of ...
See all stories on this topic

BUYINS.NET: PP, DB, FCF, IMH, LFC, SPF Have Been Added To Naked ...
Insurance News Net - Harrisburg,PA,USA
The company completed Phase II clinical trial for TRIMESTA, an oral estriol that is used for the treatment of relapsing-remitting multiple sclerosis, ...
See all stories on this topic

Multiple Sclerosis 'Risk' Genes Discovered, UK
Medical News Today Thu, 02 Aug 2007 2:12 AM PDT
A large-scale study of the human genome has uncovered new genetic variations associated with multiple sclerosis (MS).Led by an international consortium of clinical scientists and genomics experts, it is the first comprehensive study to investigate the genetic basis of MS and the researchers claim it provides the most significant genetic advancement in understanding MS for 30 years. [click link ...

New risk genes for multiple sclerosis
News-Medical-Net Wed, 01 Aug 2007 6:54 PM PDT
Two new large-scale genomic studies have honed in on the main genetic pathway associated with multiple sclerosis (MS), while also uncovering new genetic variations in the disease and suggesting a possible link between MS and other autoimmune diseases.

First Major Genetic Advance In 30 Years In Multiple Sclerosis Research
Medical News Today Wed, 01 Aug 2007 11:11 AM PDT
A newly identified gene may hold the promise of guiding future research into therapies for multiple sclerosis in what its discoverers say is the first major genetic advance in 30 years for understanding this nervous system disease. [click link for full article]

Biogen Idec shares down on Tysabri worries
Therapeutics Daily (subscription) (press release) - Newtown,PA,USA
An FDA advisory committee is set to make an up-or-down decision July 31 on Tysabri for the treatment of Crohn's disease, a gastrointestinal disorder that ...
See all stories on this topic

FDA Advisers Endorse Natalizumab (Tysabri) for Crohn's Disease
MedPage Today - Little Falls,NJ,USA
2 -- FDA advisers have recommended approval of the problem-ridden multiple sclerosis drug natalizumab (Tysabri) for treatment of moderate to severe Crohn's ...
See all stories on this topic

Biogen, Elan fall ahead of FDA hearing on Tysabri
Therapeutics Daily (subscription) (press release) - Newtown,PA,USA
... by regulators to discuss whether the companies' controversial drug Tysabri should be approved for the additional purpose of treating Crohn's disease. ...
See all stories on this topic

Scientists identify 2 genes that can cause multiple sclerosis
Austin American-Statesman (subscription) - Austin,TX,USA
After three decades of work, scientists said Sunday that they have identified two human genes that can cause multiple sclerosis, illuminating a new road ...
See all stories on this topic

Thinking inside the box. To cope with an increasing disease burden ...
Nature.com (subscription) - London,England,UK
In the USA alone, there are as many as 5.5 million individuals with Alzheimer disease, 1.5 million with Parkinson disease and 400000 with multiple sclerosis ...
See all stories on this topic

Stem Cell Therapy International Acquires Exclusive Worldwide ...
Market Wire (press release) - USA
This new method of transplanting umbilical cord stem cells that are considered compatible for anyone could, in some cases, actually replace costly and ...
See all stories on this topic

Earnings: Teva's profits slow on exclusivity loss
Jerusalem Post - Israel
The company said it wants to step up research into biopharmaceutical development and is in the final stages of clinical trials on laquinimod, ...
See all stories on this topic

Landmark Study in The Lancet: Patients Treated With Betaseron(R ...
Earthtimes.org - USA
The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment ...
See all stories on this topic

Disturbed by Sowell's sense of morality
Contra Costa Times - Walnut Creek,CA,USA
My primary progressive multiple sclerosis is possibly an entirely different disease. However, it's necessary to find the cause so a cure can be found. ...
See all stories on this topic